Spots Global Cancer Trial Database for chemoimmunotherapy
Every month we try and update this database with for chemoimmunotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer | NCT05903092 | Small Cell Lung... SCLC Extensive Stage... | Durvalumab Monalizumab Carboplatin or ... Etoposide | 18 Years - | Hoosier Cancer Research Network | |
| Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | NCT04943029 | Non Small Cell ... | Carrelizumab Pemetrexed (Non... Carboplatin Surgery | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | NCT04943029 | Non Small Cell ... | Carrelizumab Pemetrexed (Non... Carboplatin Surgery | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | NCT03836261 | Chronic Lymphoc... | Acalabrutinib Venetoclax Chemoimmunother... Obinutuzumab | 18 Years - 130 Years | Acerta Pharma BV | |
| Study of Chemoimmunotherapy for High-Risk Neuroblastoma | NCT03189706 | Neuroblastoma (... | Irinotecan temozolomide Hu3F8 GM-CSF | - | Memorial Sloan Kettering Cancer Center | |
| Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients | NCT02649582 | Glioblastoma Mu... | Dendritic cell ... | 18 Years - | University Hospital, Antwerp | |
| Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL | NCT01145209 | Small Lymphocyt... CLL (Chronic Ly... | Fludarabine Pho... Ofatumumab Cyclophosphamid... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | NCT00501644 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Carboplatin GM-CSF (Sargram... Interferon Gamm... | - | M.D. Anderson Cancer Center | |
| A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | NCT04927884 | Advanced Triple... | N-803 PD-L1 t-haNK Sacituzumab Gov... Cyclophosphamid... | 18 Years - | ImmunityBio, Inc. | |
| REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer | NCT03951831 | Prostate Cancer... | REGN2810 Degarelix Leuprolide Acet... Docetaxel | 18 Years - 99 Years | Columbia University | |
| Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer | NCT01195298 | Breast Cancer Metastasis | Capecitabine an... | 70 Years - | South Eastern European Research Oncology Group | |
| Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis | NCT03293173 | Lymphoma, Large... | R-CHOEP DA-EPOCH-R | 18 Years - 64 Years | Nordic Lymphoma Group | |
| A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer | NCT04709276 | Metastatic Pros... Metastatic Pros... | Nivolumab Ipilimumab Carboplatin Cabazitaxel | 18 Years - | Duke University | |
| A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) | NCT03571308 | Non Hodgkin Lym... | R-CHOP + acalab... | 16 Years - | University Hospital Southampton NHS Foundation Trust | |
| Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | NCT00501644 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Carboplatin GM-CSF (Sargram... Interferon Gamm... | - | M.D. Anderson Cancer Center | |
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | NCT05605535 | Ovarian Neoplas... Ovarian Cancer Fallopian Tube ... Peritoneal Carc... Ovarian Serous ... | Oregovomab Paclitaxel Carboplatin Placebo | 18 Years - | CanariaBio Inc. | |
| A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | NCT04927884 | Advanced Triple... | N-803 PD-L1 t-haNK Sacituzumab Gov... Cyclophosphamid... | 18 Years - | ImmunityBio, Inc. | |
| M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer | NCT04633252 | Cancer Of Prost... Prostate Neopla... | ADT Prednisone M7824 Docetaxel M9241 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | NCT05605535 | Ovarian Neoplas... Ovarian Cancer Fallopian Tube ... Peritoneal Carc... Ovarian Serous ... | Oregovomab Paclitaxel Carboplatin Placebo | 18 Years - | CanariaBio Inc. | |
| Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant | NCT01437709 | Mantle Cell Lym... | Ofatumumab (Thi... Ofatumumab + Be... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) | NCT04546620 | Diffuse Large B... | R-CHOP R-CHOP + acalab... | 16 Years - | University Hospital Southampton NHS Foundation Trust | |
| Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | NCT04943029 | Non Small Cell ... | Carrelizumab Pemetrexed (Non... Carboplatin Surgery | 18 Years - 70 Years | Wuhan Union Hospital, China |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
